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Bleeding from dialysis vascular access (arteriovenous fistulas, arteriovenous grafts, and vascular catheters)
is uncommon. Death from these bleeds is rare and likely to be under-reported, with incident rates of fewer than
1 episode for every 1,000 patient-years on dialysis, meaning that dialysis units may experience this cata-
strophic event only once a decade. There is an opportunity to learn from (and therefore prevent) these
bleeding deaths. We reviewed all reported episodes of death due to vascular access bleeding in Australia and
New Zealand over a 14-year period together with individual dialysis units’ root cause analyses on each event.
In this perspective, we provide a clinically useful summary of the evidence and knowledge gained from these
rare events. Our conclusion is that death due to dialysis vascular access hemorrhage is an uncommon,
catastrophic, but potentially preventable event if the right policies and procedures are put in place.
Am J Kidney Dis. 70(4):570-575. ª 2017 The Authors. Published by Elsevier Inc. on behalf of the National
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Introduction
Approximately 2.6 million people now receive
renal replacement therapy, the majority being treated
with hemodialysis (HD).1 HD requires access to the
blood circulation via a central vascular catheter
(CVC), an autologous arteriovenous (AV) ﬁstula
(AVF), or a synthetic AV graft (AVG), collectively
referred to in this article as vascular access. The
frequent use of such vascular access (up to 6 times per
week) repeatedly exposes the patient to risk for
hemorrhage from a variety of causes. The aim of this
perspective is to review what is known about fatal
hemorrhage related to HD vascular access, including
the current epidemiology, risk factors, and preventive
practices. We provide clinical insights from reported
deaths due to vascular access bleeding in Australia and
New Zealand (ANZ) over a 14-year period, together
with individual dialysis units’ root cause analyses.
Epidemiology of Fatal Vascular Access Hemorrhage
Fatalities due to vascular access hemorrhage in the
reported literature are rare. Ellingson et al,2 examining
data from the United States in 2000 to 2007, found
that 0.4% of dialysis deaths (n 5 88) attributed to
fatal vascular access hemorrhage (FVAH), and Suri
et al,3 0.8% (n 5 2) in the assessment of data from
the Frequent Hemodialysis Network (FHN) Daily
Trial. Gill et al4 reported 100 deaths due to FVAH
between 2003 and 2011 in the United States, whereas
Mazzoleni et al5 reported 2 FVAH deaths in Belgium
between 2005 and 2012. The US Veterans Health
Administration Center for Patient Safety analyzed 47
episodes of bleeding during dialysis between 2002
and 2008, of which “some of these resulted in
fatalities.”6(p1)
Using a systematic search strategy of the National
Coronial Information System (containing coroner’s
reports from all Australian states and New Zealand,
www.ncis.org.au), the ANZ Dialysis and Transplant
Registry (ANZDATA, www.anzdata.org.au), pub-
lished cases from ANZ, State Renal Network reports,
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and individual renal units, we identiﬁed all ANZ cases
for which cause of death was reported as death due to
dialysis access hemorrhage during the 14 years from
2000 to 2013 (Fig S1, available as online supple-
mentary material). After removal of duplicates and
alternate causes of death, we identiﬁed 79 people as
having died from FVAH. During the period of
observation, the annual number of deaths ranged from
2 to 10 in any given year (Fig S2). As also observed
by others, we found incidence to be low. For example,
in 2013, there were 9,468 people on HD therapy in
Australia and 1,752 in New Zealand,7 and of the
1,508 deaths in ANZ dialysis patients that year, 9
were attributable to FVAH, therefore contributing to
0.6% of HD deaths overall, or approximately 1 death
for every 1,250 patient-years of HD.
Such a low incidence of FVAH means that most
dialysis units are likely to ever encounter only 1 fatal
event. This tenet is supported by observations of
Ellingson et al,2 who described 88 conﬁrmed cases
over a 90-month period from 58 US dialysis facilities,
with a maximum of 3 in any 1 unit. On the other hand,
Mazzoleni et al5 reported all cases of hemorrhage,
fatal or not, and determined a higher rate of 0.045
hemorrhage/1,000 patient-days, suggesting that near-
miss events are substantially more common.
Pathophysiology of Vascular Access Hemorrhage
Based on previous reports in the literature,2,4,5,8 3
broad groups of causal factors for FVAH may operate
independently or in combination. First, speciﬁc
complications associated with the vascular access,
such as aneurysmal formation and/or bacterial infec-
tion, lead to weakening of the vessel wall, increasing
the subsequent risk for bleeding. Second, patient-
related factors, including multiple comorbid condi-
tions and medications, may contribute to increased
bleeding risk, including reduced cognitive function
and the ability to self-manage an initial bleed.
Third, dialysis procedure–related factors, speciﬁcally
disconnection at the patient-machine interface
(including detection of needle dislodgement or cath-
eter misconnection), may lead to an FVAH.
Risk Factors for FVAH
Due to the rarity of FVAH, assessing independent
risk factors is difﬁcult. However, several potential risk
factors can be ascertained. The type of vascular access
in use appears to be an important risk factor for
FVAH. In the ANZ cohort we analyzed, 20% and
22% of FVAH events occurred in AVGs and CVCs,
respectively (Table S1), markedly higher than their
overall use in ANZ during this period (prevalent use
in ANZ at December 31, 2013, was 7% for AVGs and
14% for CVCs).7 Similarly, Ellingson et al2 identiﬁed
AVGs as a risk factor, with cases of FVAH having a
6-fold greater likelihood of using an AVG compared
with 38 control patients (controls were randomly
selected from the same dialysis facility, but had died
of non–vascular access hemorrhage causes). Synthetic
AVGs are more prone to pseudoaneurysm formation
than AVFs due to their higher intra-access pressure
and lack of venous tissue at the puncture site, mean-
ing that repair mechanisms are limited to clot and
ﬁbrous tissue.9 Pseudoaneurysm formation increases
the likelihood of spontaneous rupture of the vessel.10
CVCs were also a risk factor for FVAH in our data,
contributing to 17 (22%) deaths for which site of
bleeding was recorded. Of the 17 fatal CVC bleeds,
10 related to insertion or removal procedures and 4
were disconnections during a dialysis session
(Table 1). In the literature, exsanguination from
disconnection of CVCs is mostly reported in case
series11-13 and is not as well studied as needle
dislodgement from AV access.6 The US Veterans
Affairs National Center for Patient Safety reported
that 20% of all (fatal and nonfatal) bleeding episodes
were attributable to CVCs (often in the intensive care
unit or dialysis isolation rooms),6,14 similar to the
21% for FVAH found by Ellingson et al.2 In reported
cases of bleeding from CVCs, the most common
reasons included failure to cap catheter ports, loose
connections with the dialysis machine circuit, and
inadvertent removal.15-18 Although catastrophic, it
should be realized that exsanguination from CVCs is
an infrequent complication. In absolute terms, other
Table 1. Recorded Cause of Death
Cause of Death n/N (%)
Bleeding arteriovenous access
AVF 48/79 (61)
AVG 11/79 (14)
Catheter insertion or removal bleed 10/79 (13)
Catheter disconnection bleed 4/79 (5)
Postoperative AVF bleed 2/79 (3)
Bleeding catheter not otherwise specified 2/79 (3)
Suicide; cut catheter 1/79 (1)
Misconnection of dialysis tubing (AVF) 1/79 (1)
Note: Data obtained from the analysis of 79 deaths in Australia
and New Zealand between 2000 and 2013. Cause of death was
identified by coronial reports on the NCIS, local unit root cause
analyses, and as reported to ANZDATA. At the time of writing,
5 coronial cases were not concluded, 4 of which were reported
to ANZDATA as “AVF bleeds.” Ethical approval for this study
was obtained from the Human Research Ethics Committee
(Tasmania) Network (approval H0013985), the Victorian
Department of Justice Human Research Ethics Committee (CF/
14/15524), and the Coronial Ethics Committee of Western
Australia (EC06/14).
Abbreviations: ANZDATA, Australia and New Zealand
Dialysis and Transplant Registry; AVF, arteriovenous fistula;
AVG, arteriovenous graft; NCIS, National Coronial Information
System.
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complications with CVCs, most notably catheter-
related bloodstream infection, can be up to 100
times more frequent in HD populations (5.1 episodes/
1,000 catheter-days19 compared to 0.045 episode/
1,000 patient-days for bleeding complications5).
The physical location of the vascular access may
also be important; 6% of all deaths in our series were
from a thigh vascular access (Table 2), which was
similar to the 8% reported by Gill et al.4 This is likely
over-represented as a contributor to fatal bleeds due to
the large vessel size and consequent higher blood ﬂow
and intra-access pressure making it more difﬁcult to
control bleeding.
Infection of the AV access is an important risk
factor due to interference of the usual repair mecha-
nisms leading to weakness in the vessel wall, potential
for subsequent aneurysm or pseudoaneurysm forma-
tion, and risk for eventual rupture. Recent infection or
problems with skin integrity were reported for 16 of
31 AVF or AVG bleeds (52%) in our cohort,
including 3 of the 10 who had recent surgical
correction (Table 2). Infection was also the most
common vascular access complication seen in the 6
months before fatal hemorrhage in the study from
Ellingson et al2 and was identiﬁed in 5 of the 6 AVF
bleeds (83%) reported by Mazzoleni et al.5 Button-
hole cannulation techniques13,20,21 have been clearly
shown to increase the risk for vascular access infec-
tion and therefore may also be a potential risk factor
for hemorrhage, but to our knowledge, reporting of
cannulation method is not in any published reports of
FVAH to date.
Finally, where the person is when the bleed occurs
may be an important risk factor for hemorrhage itself,
but also may inﬂuence the subsequent risk for death
directly related to that hemorrhage (due to lack of
readily available expertise to manage the bleeding).
Reports of FVAH in facility-based dialysis patients in
the United States found that the majority (78%) of
bleeding episodes occurred while patients were in the
community (home or nursing home), with only 12%
occurring during a dialysis session. Gill et al4 also
reported on facility-based dialysis patients, showing
that 81% of bleeds occurred while the patient was in
the community, away from the dialysis unit. Data
from our ANZ cohort demonstrates a similar ﬁnding,
with most FVAHs occurring in the home or com-
munity setting (78%), and the rest occurring in the
satellite dialysis unit (5%) or hospital setting (17%;
Table S1). However, ANZ data are limited because in
49% of cases, location was not recorded.
For people dialyzing in the home (who have
extensive training in self-management and often a
dialysis partner present), Pauly et al reported the
relative risk for death from vascular access bleed or
infection in home to be 0.27 (95% conﬁdence inter-
val, 0.20-0.37) versus facility HD patients, consistent
with the observation that serious safety events on
home dialysis are rare.22 Of 79 deaths in our ANZ
cohort, 12 patients were treated with home-based HD
at the time of death, of whom 9 died from a bleeding
AVF/AVG (place of death was not recorded in 6), 1
from CVC disconnection while receiving home
dialysis, 1 from CVC insertion (in hospital), and 1
from misconnection of dialysis tubing (previously
published23).
Prevention of FVAH
Most literature on the prevention of FVAH is
focused on the prevention of bleeding while receiving
dialysis, which generally occurs from venous needle
dislodgement or catheter misconnection. It is now
well established that arterial and venous pressure
alarms on dialysis machines are not sensitive enough
to detect partial dislodgment14,24,25 and that rapid
blood loss leads to hemorrhagic shock within only 1
to 2 minutes at usual blood ﬂow rates. Many recom-
mendations have been made in the literature to
counter such events, such as proper taping of needles,
tightening of connections, or the use of Luer lock
devices, loose looping of blood tubing, blood leakage
sensors, and heightened surveillance for confused
patients.6,14,26-28 However, as stated, both ANZ and
US data conﬁrm that the vast majority of fatal bleeds
Table 2. Identified Issues That May Have Contributed to Death
Identified Issue Source of Data
Total No. of Cases in
Data Sources
No. Where
Data Recorded Issue Present
Recent access infection or problems with
skin integrity (within 4 wk) of AVF/AVG
NCIS, unit RCA 49 31 16/31 (52%)
AVF/AVG declotted in previous 12 mo ANZDATA 66 53 6/53 (13%)
AVF/AVG revised in previous 12 mo ANZDATA 66 53 11/53 (21%)
Use of a thigh AVF/AVG NCIS, unit RCA 49 14 5/14 (36%)
Coronial open cases (not yet finalized) NCIS 48 48 5/48 (10%)
Note: Data obtained from the analysis of 79 deaths in Australia and New Zealand between 2000 and 2014. Issues were identified by
coronial reports on the NCIS, unit RCA, and access interventions as reported to the ANZDATA.
Abbreviations: ANZDATA, Australia and New Zealand Dialysis and Transplant Registry; AVF, arteriovenous fistula; AVG, arterio-
venous graft; NCIS, National Coronial Information System; unit RCA, unit root cause analyses.
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occur from spontaneous access rupture away from the
dialysis facility (most often at home, assisted living,
or a nursing home), and it is therefore likely that the
family and caregivers are confronting these large
bleeds,29 rather than dialysis unit staff.
The sharing of individual unit or network mortality
review ﬁndings has allowed us to collate and share
their recommendations (Box 1). We have categorized
these into vascular access–, patient-, procedure-,
and facility-related recommendations. Of these,
the largest and most challenging areas for improve-
ment are facility-related (clinical governance) and
patient-related (education) areas, because often the
ﬁeld’s previous focus has been on vascular access and
the dialysis procedure.
It is essential that AV access be examined
physically on a frequent and routine basis: wet scab-
bing, frank infection, or pseudoaneurysm should
trigger urgent review and intervention. However,
there are only a few dialysis facilities in ANZ that
systematically collect and report loss of skin integrity
overlying the puncture site for routine adverse-event
reporting.30 There is a need for standardized moni-
toring and reporting of AV puncture site integrity, in a
Box 1. Summary of Recommendations and Local Practice Change From Coronial Inquiries, Journal Publications, Renal Network,
and Local Unit Reviews in Australia and New Zealand
Vascular Access–Related Recommendations
Fistula/graft
! Clinical examination of AVF/AVG should occur each dialysis episode
! Vascular access site must remain visible throughout dialysis
! Documentation that cannulation site of AVF/AVG was rotated should be recorded with consideration of a cannulation plan
! Suspicion of infection should be immediately communicated to the vascular access coordinator or medical officer
! Access infection should be treated and monitored until resolution
! Confirmed bloodstream infections require a minimum duration of antibiotic treatment
Dialysis catheters
! Catheter connections should be checked and documented by 2 nurses
! Catheter connections should be checked hourly during dialysis and documented
! Catheters and their connections should be visible above clothing/blankets throughout the dialysis procedure
Patient-Related Recommendations
Patient considerations
! Medical staff should regularly review patient comorbid conditions, including medications and consider potential impact on
bleeding risk
! Dialysis anticoagulation prescriptions should be regularly reviewed by medical staff
Education
! Education of both patients and staff is critical, with preference for a structured education program and provision of resources to
patient
! As a minimum, all should be educated on the need to rotate cannulation site, the risk for bleeding, and immediate first aid
! Education resources have been developed by the NSW Agency for Clinical Innovation, including an information sheet,
management algorithm, and “Heed the Herald Bleed” poster (http://www.aci.health.nsw.gov.au/networks/renal/resources)
Dialysis-Related Recommendations
Equipment modifications
! Consider use of a wetness detector for catheters or frail patients
! Isolation rooms should have real-time visual monitoring by staff
! Dialysis machine modifications should include the ability to detect blood leak during dialysis
! Catheter connection modifications to prevent dialysis tubing from being misconnected or disconnected
Facility-Related Recommendations
Clinical governance
! Renal units should have a management algorithm for identification, reporting, and management of altered skin integrity or
bleeding associated with dialysis vascular access
! A single point of care, such as a Vascular Access Nurse Coordinator, should be considered
! Renal units should have a clear clinical communication, escalation, and handover process
! The access coordinator should maintain documentation of AVF/AVG problems, clinical review, and escalation to medical staff
! Renal units should have a standard protocol for antiseptic preparation that includes alternative options for management of skin
sensitivities
! Renal units should have a standard effective taping method of dialysis cannulas
! All vascular access hemorrhage deaths should undergo unit review and results disseminated across state/national health
network and be considered for publication if considered a safety issue
! All critical safety events should be reported to the relevant authority
Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; NSW, New South Wales.
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manner that is analogous to the reporting of exit-site
infections in peritoneal dialysis programs. This need
is most acute in high-risk patients such as those
exposed to buttonhole cannulation or with immuno-
suppressive diseases or those who have undergone
recent intervention to the access.
Appropriate education should be guided by the
observation that fatal bleeding almost always
occurs away from the dialysis facility. It is critical
that patients and their caregivers are taught how
to respond appropriately to episodes of bleeding
that occur in the interdialytic period. A structured
teaching program should be implemented, with
content based around current recommendations in
the literature8,27: direct continuous pressure for 15 to
20 minutes until emergency medical help arrives,
avoiding the application of tourniquets, blood
pressure cuffs, or bandages to the extremity. The
largest state in Australia (by both general and
dialysis populations) has taken the lead on this issue,
developing educational resources about AV access
bleeding for both patients and staff and implemented
at a state-wide level (Box 1). These efforts represent
a start in this area, with concepts and deliverables
that should be expanded through policy initiatives at
a national level and enhanced for high-risk sub-
groups. For instance, recipients of HD are now
commonly in the 8th and 9th decade with multiple
comorbid conditions, including cognitive decline.
The ability of patients to learn self-management of
bleeding episodes may be limited, and a different
coaching approach and clinical algorithm may be
necessary.
Clinical governance requires effective clinical
practice and policy from the individual patient to the
national level, with the latter being even more
important for these rare (but preventable) events. It is
important to realize that education is only one
component of what should be a whole system
approach for the prevention of FVAH. This approach
should be guided by systematic quality assurance
principles. Critical preventative measures include
achieving puncture site integrity at the end of each
HD treatment (allowing the patient to leave the dial-
ysis unit safely) and regular access monitoring in the
dialysis facility to detect wet scabbing, infection, or
pseudoaneurysm. Critical mitigation measures
include the patient education described. All the ac-
tivities should be nested in a heightened clinical cul-
ture of quality assurance around FVAH to drive
appropriate detection and management. This should
be reﬂected in facilities having clear and well-
socialized clinical pathways designed to trigger pre-
ventative actions to avert FVAH and appropriate
operating mechanisms for managing near misses and
each patient who is detected to have an at-risk access.
The ability to demonstrate effective quality
improvement at a single-unit level for such uncom-
mon events is difﬁcult, and reporting at a network,
state, or federal level is necessary.
A major limitation of the current literature is the
lack of sufﬁcient detail of the event leading to and
surrounding each episode of FVAH. For instance, in
our study, we lacked access to data that may have
been informative, such as the access cannulation
technique (eg, use of buttonhole cannulation), type
and amount of anticoagulation used for the dialysis
episode before death, use of antiplatelet agents, and
speciﬁc details on the vascular access in the days
leading up to death relating to the type of local in-
fections, venous pressures, recent effectiveness of
dialysis, and physical location of the vascular access
(leg or arm). Low-molecular-weight heparins, now
widely used in HD in some countries, are renally
cleared and may have a prolonged and cumulative
effect in end-stage kidney disease, beyond the time
required for actual dialysis, putting the patient at
risk in the postdialysis period.31 Finally, the current
literature includes only FVAH, rather than near mis-
ses: these latter cases are critical learning tools for
dialysis providers for maintaining patient safety.22
There are important learning opportunities, based on
rigorous collection, analysis, and sharing of data on
all major bleeding episodes in people treated with
HD, that must occur to better understand and prevent
future FVAH.
Conclusions and Area for Future Research
In conclusion, deaths occur every year due to
FVAH, an uncommon but preventable complication
of dialysis. There is a need for more speciﬁc data for
all bleeding events, not just the fatal ones, to better
understand this sentinel event. Appropriate preventa-
tive measures include implementation of robust
quality assurance processes and reporting around the
AV puncture site integrity, accompanied by clear
clinical pathways to trigger review and intervention.
This should be coupled with the development of
health literacy–appropriate and culturally sensitive
education materials to help patients detect and self-
manage VA bleeding episodes outside the dialysis
facility.
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